Mithra Obtains First Marketing Authorization for Myring™ in Europe

  • Marketing authorization allows for launch of Myring™ in the United Kingdom
  • Additional marketing authorizations expected in the near future
  • Mithra to produce Myring™ at its CDMO
Liège, Belgium, 20 July 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the company obtained its first marketing authorization (MA) for Myring™  in the UK, following approval by the MHRA . Myring™ is Mithra’s contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA) and is developed to be fully bioequivalent to Merck’s Nuvaring®.  In April 2018, Nuvaring® went off patent in both the US and Europe. In the UK, which is a market worth approximately EUR 1.2 million , no generic competition exists as of yet.